Archive · 17 Dec 2025
AstraZeneca Approved to Import Breast Cancer Drug
AstraZeneca Pharma India has received approval from the CDSCO to import and sell a new drug called Datopotamab Deruxtecan.
This drug is used to treat a specific type of breast cancer in adults.
The company's shares on the stock market went down a little bit after this news.
The drug is for people who have a kind of breast cancer that can't be removed by surgery or has spread to other parts of the body.
It's important for a type of breast cancer that is hormone receptor-positive and HER2-negative.
AstraZeneca Pharma India received CDSCO approval to import and market Datopotamab Deruxtecan for breast cancer treatment.
The drug is indicated for adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer.
AstraZeneca Pharma India's shares ended at ₹8,984.50, down by ₹32.00 or 0.35% on the BSE.
Datopotamab Deruxtecan is a powder for concentrate for solution for infusion, 100 mg, of r-DNA origin.
The approval allows the company to bring this specific cancer treatment to the Indian market.
- Who
- AstraZeneca Pharma India
- What
- Approval to import and market Datopotamab Deruxtecan for breast cancer treatment
- When
- Not specified
- Where
- India
- Why
- To treat adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer
- Company
- AstraZeneca Pharma India
- Drug Name
- Datopotamab Deruxtecan
- Treatment For
- Unresectable or metastatic, HR-positive, HER2-negative breast cancer
- Approval Authority
- CDSCO
- Stock Price
- ₹8,984.50
- Stock Change
- Down by ₹32.00 (0.35%)